1236 related articles for article (PubMed ID: 25595028)
1. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
2. [Application of gene therapy in tumor adoptive immunotherapy].
Wang C; Zhao Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
[TBL] [Abstract][Full Text] [Related]
3. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
6. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Li H; Zhao Y
Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
[TBL] [Abstract][Full Text] [Related]
7. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.
Kuramitsu S; Yamamichi A; Ohka F; Motomura K; Hara M; Natsume A
Immunotherapy; 2016 Dec; 8(12):1393-1404. PubMed ID: 28000534
[TBL] [Abstract][Full Text] [Related]
9. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
10. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
11. Development of adoptive cell therapy for cancer: a clinical perspective.
Hawkins RE; Gilham DE; Debets R; Eshhar Z; Taylor N; Abken H; Schumacher TN; ATTACK Consortium
Hum Gene Ther; 2010 Jun; 21(6):665-72. PubMed ID: 20408760
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy: past, present and future.
Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
[TBL] [Abstract][Full Text] [Related]
14. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
15. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
16. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
18. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
19. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Eshhar Z
Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]